CORRECTED - UPDATE 1-Amylin posts wider second-quarter net loss
(Corrects paragraph 4 to say revenue came close to Wall Street estimates, instead of beating)
LOS ANGELES, July 21 (Reuters) - Amylin Pharmaceuticals Inc (AMLN.O: Quote, Profile, Research, Stock Buzz) reported a wider quarterly loss on Monday, hurt by higher expenses.
The San Diego-based biotechnology company posted a second-quarter net loss of $64.8 million, or 47 cents per share, compared with a loss of $45 million, or 34 cents per share, a year ago.
Wall Street analysts, on average, expected a loss of 49 cents per share, according to Reuters Estimates.
Revenue rose nearly 13 percent to $222 million, close to analysts' target of $224.3 million. Net sales of diabetes drug Byetta, which Amylin co-markets with Eli Lilly and Co (LLY.N: Quote, Profile, Research, Stock Buzz), rose 17 percent to $177.5 million.
Shares of Amylin, which closed up 3.3 percent at $26.60 on Nasdaq, were little changed at $26.58 in after-hours trading. (Reporting by Deena Beasley; editing by Jeffrey Benkoe)
© Thomson Reuters 2008 All rights reserved
Ads by Career Builder
Medical & Healthcare Opportunities
Details: ...in life. Medical / Healthcare Some of the opportunities...in the Medical and Healthcare area include: Dental...
Healthcare Engagement Manager
Details: ...an experienced healthcare consultant who has...completion? Healthcare Engagement Managers...They use their healthcare expertise to become...
Vice President of Healthcare Sales
Details: ...President of Healthcare Sales is...develop the healthcare services market...President of Healthcare Sales prospects...
Healthcare Recruiter/Entry-Level Sales Management
Details: Maxim Healthcare Services is...leader in the healthcare industry through...industry. Maxim Healthcare Services is recognized...







